FIELD: biotechnology.
SUBSTANCE: PSMA-binding antibody is proposed. The antibody is characterized in reduced degree of antigen shift induction and unique reactivity relatively to cells of squamous cell carcinoma (SCC) of different origin.
EFFECT: obtaining new PSMA-binding antibody.
3 cl, 17 dwg, 1 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED ANTI-FLT3 ANTIGEN-BINDING PROTEINS | 2019 |
|
RU2830982C2 |
| CD3-SPECIFIC BINDING MOLECULES | 2020 |
|
RU2826453C2 |
| PROTEASE-ACTIVATED T-CELL BINDING BISPECIFIC MOLECULES | 2017 |
|
RU2830288C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3 | 2020 |
|
RU2827106C1 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2790288C2 |
| CD3 BINDING ANTIBODIES | 2017 |
|
RU2807216C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| MODIFIED J-STRAIN | 2015 |
|
RU2761118C2 |
